Led · Series C · Mar 2026

Endogenex develops a minimally invasive procedure that targets cellular pathology in the duodenum to restore metabolic signaling. Its Endogenex System applies highly controlled, non-thermal pulsed electric fields to the mucosa and submucosa to support healthy cell regeneration. The company is clinical-stage and has evaluated the technology in feasibility studies including REGENT-1 US, REGENT-1 Australia, and EMINENT in the Netherlands, with preliminary outcomes presented at medical conferences. Endogenex is led by CEO Stacey Pugh and is based in Minneapolis, MN. In June 2024 it closed an $88M Series C and in March 2026 raised a $50M Series C extension, bringing total Series C financing to $138M.

Led · Series A · Feb 2026

Minneapolis-based Pharaoh Neuro is a medical device company advancing two key technologies: the Neurapheresis cerebrospinal fluid (CSF) management system and the MindsEye expandable port for minimally invasive cranial access. Neurapheresis is a closed-loop platform that circulates and filters a patient’s own CSF without introducing replacement fluids, aiming to reduce complications and give clinicians greater control in treating critically ill neurological patients. MindsEye, first cleared by the FDA in 2020 while under Minnetronix Medical, is being prepared for reintroduction to the U.S. market under Pharaoh Neuro’s stewardship. The company recently appointed Amaza Reitmeier, former VP & GM of Neuromodulation at Medtronic, as CEO, and Dr. Nandan Lad, the inventor of the core technology, as chief medical officer. With its newly raised funds, Pharaoh Neuro plans to pursue further development and regulatory clearance for Neurapheresis and to relaunch MindsEye. The leadership’s stated goal is to reshape the standard of neurocritical care through evidence-based clinical introduction of its platform.

Led · Series B · Sep 2025

Boomerang Medical is a women-led bioelectronic medicine company headquartered on the El Camino Hospital campus in Mountain View, California, led by CEO Heather Simonsen. The company develops implantable neuromodulation treatments for autoimmune diseases and is advancing BOOM-IBD2, described as the first pivotal trial of implantable neuromodulation in inflammatory bowel disease with an initial focus on ulcerative colitis. It completed a 40-patient feasibility study in Crohn's disease and ulcerative colitis, and those results informed the design of BOOM-IBD2. Boomerang notes that sacral neuromodulation has a long safety record, with more than 500,000 procedures performed worldwide. The company is a Company-In-Residence at Fogarty Innovation and was recognized as an "Emerging Leader in IBD" by the Crohn’s & Colitis Foundation. It plans to use the newly raised funds to advance the BOOM-IBD2 pivotal trial. Boomerang Medical develops a neuromodulation technology that harnesses the body’s peripheral wiring to manage inflammation and immune response for autoimmune diseases. The company is clinical-stage and recently received FDA authorization to commence the Boomerang Clinical Trial for patients with Inflammatory Bowel Disease (IBD). Boomerang is using its device-oriented approach to target hard-to-treat autoimmune conditions, with an initial focus on IBD (including Crohn’s disease and ulcerative colitis). Management is led by President and CEO Heather Simonsen, and the company is a Company‑In‑Residence at Fogarty Innovation on the El Camino Health campus. Boomerang plans to use the new financing to advance clinical studies of its neuromodulation platform. The company is headquartered in Mountain View, Calif.

Participated · Series B · Aug 2025

Reprieve Cardiovascular is a clinical-stage medical device company headquartered in Milford, Massachusetts, developing the Reprieve system to personalize decongestion management for patients with acute decompensated heart failure (ADHF). The Reprieve system combines real-time physiological monitoring with automated recommendations and precise diuretic dosing while replenishing saline to support kidney function, aiming to safely, quickly, and thoroughly remove excess fluid. The company completed a randomized FASTR pilot study that met primary efficacy and safety endpoints and has initiated the larger FASTR II pivotal trial, enrolling its first patient. FASTR II plans to enroll up to 400 patients across the United States and Europe and will support a future premarket approval submission in the United States. Proceeds from the oversubscribed $61 million Series B, which combined equity investment with a debt facility, will support rapid execution of the FASTR II trial and key commercial readiness activities. Reprieve says it seeks to improve outcomes and reduce readmissions for the more than 25 million people globally who suffer from heart failure. Reprieve Cardiovascular is a development-stage, privately held medical device company developing the Reprieve System, an intelligent automated diuretic and fluid-management platform to personalize decongestion for acute decompensated heart failure patients. The system monitors physiological parameters such as urine output to deliver personalized diuretic dosing and fluid replacement, aiming to safely and quickly remove excess fluid, improve outcomes, and reduce readmissions. The company emerged from stealth after announcing a $42 million Series A to advance clinical and development programs. Proceeds will support the ongoing FASTR pilot trial (initiated in 2022) and an upcoming pivotal trial; the FASTR trial is enrolling patients in the United States and Europe. Leadership has grown with domain experts across product development, regulatory, clinical, and commercial strategy. Reprieve is headquartered in Milford, Massachusetts.

Participated · Series D · Jun 2025

Allay Therapeutics is a clinical-stage biotech pioneering ultra-sustained analgesic products that combine validated non-opioid analgesics (bupivacaine) with biopolymers to deliver weeks of localized pain relief. Its lead candidate, ATX101, is an investigational formulation of bupivacaine designed to provide extended analgesia after surgery and is placed at the end of standard surgery to dissolve over weeks. The company is enrolling a 200-participant Phase 2b registration trial in total knee arthroplasty (TKA) initiated in February 2025, with results anticipated in Q4 2025 and a Phase 3 planned for 2026. ATX101 previously showed durable treatment effects versus standard-of-care bupivacaine in a prior dose-ranging Phase 2b, with less opioid use and improved function, and has received FDA Breakthrough Therapy designation. Allay has R&D teams in Singapore and the U.S., and its partner Maruishi Pharmaceutical is conducting a Phase I/II safety study in Japan and has expanded its license territory to South Korea and Taiwan. Proceeds from the recent financing and venture debt will advance the ATX101 Phase 2b registration trial and the company’s broader ultra-sustained pain platform. Allay Therapeutics is developing thin, coin‑sized biodegradable implants that are placed around an implanted knee joint to deliver a validated non‑opioid local anesthetic in a controlled fashion for up to three weeks. The company’s novel active ingredient–polymer architecture extends analgesic delivery an order of magnitude beyond existing local systems and the implants gradually dissolve as they release drug. Evonik supplies the biodegradable polymers used in the devices and has invested in the company, and Allay is positioning the technology as an alternative to systemic opioids to improve and accelerate recovery. Allay’s products are in early stages of clinical development and the firm is developing a portfolio of candidates based on the same drug‑polymer architecture for other orthopedic and soft‑tissue surgeries. The technology was developed in Singapore and Allay maintains R&D facilities there while being headquartered in San Jose, California. The company highlights the large U.S. market—more than 1.2 million knee joint interventions per year and an estimated $10 billion treatment volume for severe postoperative pain—against the backdrop of the opioid crisis. Allay Therapeutics is a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation. Its proprietary platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates that deliver targeted pain relief over weeks. The company’s lead candidate, ATX-101, is being advanced into a Phase 2b study in total knee arthroplasties in the United States. R&D teams in Singapore and the Bay Area have developed proof-of-concept implant variants, injectable formulations, on-demand self-dosing formulations, and formulations incorporating additional small molecules and local analgesics. Allay intends to advance at least one new clinical candidate into trials each year and is building manufacturing capabilities in the Bay Area to support future product launches. The company completed an oversubscribed $60M Series C to support clinical and platform development.